Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05645380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Mar 2026 to Dec 2026Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 2026 to Dec 2028 · Site details revised at 7 of 7 sitesv6Show 3 more changesShow less
Trial status: Recruiting to Active, Not Recruiting
Completion date: Dec 2026 to Dec 2028
Site details revised at 7 of 7 sites
MinorPrimary completion date: Dec 2025 to Mar 2026v5
NotablePrimary completion date: Dec 2024 to Dec 2025Completion date: Dec 2025 to Dec 2026 · Eligibility criteria expanded, about 73 wordsv4Show 2 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStart date changed from estimate of Dec 2022 to Dec 5, 2022 · Site details revised at 6 of 6 sitesv2Show 2 more changesShow less
Start date changed from estimate of Dec 2022 to Dec 5, 2022
Site details revised at 6 of 6 sites
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.